Contributions of Interleukin-1 Receptor Signaling in Traumatic Brain Injury
| Autor: | Matthew J. Robson, Poornima Gopalan, Jason G. Thome, Evan L. Reeder, Sean M. Collins |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.drug_class
Traumatic brain injury Cognitive Neuroscience medicine.medical_treatment Mini Review microglia Context (language use) Interleukin-1 receptor Bioinformatics Proinflammatory cytokine lcsh:RC321-571 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine astrocyte cytokine Medicine lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Neuroinflammation 030304 developmental biology 0303 health sciences interleukin-1 receptor business.industry traumatic brain injury Interleukin Receptor antagonist medicine.disease Neuropsychology and Physiological Psychology Cytokine business 030217 neurology & neurosurgery interleukin-1 Neuroscience |
| Zdroj: | Frontiers in Behavioral Neuroscience Frontiers in Behavioral Neuroscience, Vol 13 (2020) |
| ISSN: | 1662-5153 |
| Popis: | Traumatic brain injury (TBI) in various forms affects millions in the United States annually. There are currently no FDA-approved therapies for acute injury or the chronic comorbidities associated with TBI. Acute phases of TBI are characterized by profound neuroinflammation, a process that stimulates the generation and release of proinflammatory cytokines including interleukin-1α (IL-1α) and IL-1β. Both forms of IL-1 initiate signaling by binding with IL-1 receptor type 1 (IL-1R1), a receptor with a natural, endogenous antagonist dubbed IL-1 receptor antagonist (IL-1Ra). The recombinant form of IL-1Ra has gained FDA approval for inflammatory conditions such as rheumatoid arthritis, prompting interest in repurposing these pharmacotherapies for other inflammatory diseases/injury states including TBI. This review summarizes the currently available preclinical and clinical literature regarding the therapeutic potential of inhibiting IL-1-mediated signaling in the context of TBI. Additionally, we propose specific research areas that would provide a greater understanding of the role of IL-1 signaling in TBI and how these data may be beneficial for the development of IL-1-targeted therapies, ushering in the first FDA-approved pharmacotherapy for acute TBI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|